Drugs / NUVISERTIB
NUVISERTIB
Trials 4 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 13 trials | ||||||
| Phase 1 | NCT07492355 | Mar → May 2024 | myelofibrosis | Sumitomo Pharma America, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT06389955 | May → Aug 2023 | — | Sumitomo Pharma America, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT03715504 | Apr 2019 → Mar 2021 | cancer | Sumitomo Pharma America, Inc. | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT04176198 | Dec 2019 → Apr 2027 expected | myelofibrosis | Sumitomo Pharma America, Inc. | Recruiting | No outcome recorded |
Evidence & citations 7 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | NUVISERTIB | ChEMBL registry synonym — accepted as the source's own label CHEMBL3975308 ↗ |
| Known as | Nusivertib | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04176198 ↗ |
| Known as | SGI-9481 | ChEMBL registry synonym — accepted as the source's own label CHEMBL3975308 ↗ |
| Known as | TP-3654 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07492355 ↗ |
| Action | Inhibit | “oral PIM inhibitor” NCT03715504 ↗ |
| Modality | Small molecule | — CHEMBL3975308 ↗ |
| Route | Oral | “TP-3654 by oral administration” NCT03715504 ↗ |